Doctor Who Sparked Vaccine Controversy Faces Charges
The doctor who sparked a worldwide scare over the safety of the MMR vaccine is expected to be charged with professional misconduct by Great Britain's General Medical Council, the London Independent reported Monday.
Dr. Andrew Wakefield, whose 1998 research paper published in the British medical journal The Lancet purported to show a link between the measles, mumps and rubella vaccine and autism, is accused in preliminary charges of publishing "inadequately founded" research, failing to obtain ethical committee approval, obtaining funding "improperly," and of subjecting children to "unnecessary and invasive investigations," according to the newspaper.
Detailed charges against Wakefield, 50, are being formulated by the GMC's lawyers and a public hearing is expected next year. If Wakefield is found guilty, he could be struck from the medical register, the Independent reported.
After Wakefield and 12 other doctors published the warning about the combined vaccine, tens of thousands of parents boycotted its use, leading to rising cases of all three illnesses.
The research was said to have done more damage than anything published in a scientific journal in living memory, according to the newspaper.
New Diabetes Drugs Add Double Punch to Older Medications
Two experimental pills seem to pack a one-two punch for older diabetes drugs -- they not only help lower blood sugar levels but also help with weight loss.
The once-a-day medications are the first in a new class of type 2 diabetes drugs that manufacturers Merck & Co. and Novartis AG hope to win U.S. Food and Drug Administration approval for and to begin selling by year's end, the Associated Press reported Tuesday.
Merck's pill, Januvia or sitagliptin, lowered blood sugar levels by 0.67 percent for participants in a yearlong trial, or just as much as another, older drug, glipizide, the AP reported. Novartis' pill, Galvus or vildagliptin, reduced blood sugar levels by 1.9 percent when used with another older drug, pioglitazone, which reduces insulin resistance.
Excess weight is a common problem in type 2 patients. Both experimental pills helped patients maintain or even lose weight in the trials. Side effects of the pills included cold and flu-like symptoms and headaches.
FDA OKs Antidepressant to Treat Winter Blues
Federal regulators on Monday approved GlaxoSmithKline's antidepressant Wellbutrin XL to help treat the estimated half a million people in the United States who suffer from winter depression.
The U.S. Food and Administration said the drug is the first to be approved to treat the condition, which causes bouts of recurrent depression, and is known as seasonal affective disorder, or SAD. Wellbutrin XL (bupropion HCL extended release tablets) had been previously approved for treatment of major depressive disorder.
"The effectiveness of Wellbutrin XL for the prevention of SAD episodes was established in 3 double-blind, placebo-controlled trials in adults with a history of major depressive disorder in autumn and winter," the FDA said in a prepared statement. "Treatment was initiated prior to the onset of symptoms in the autumn (September to November) and was discontinued following a two-week taper that began the first week of spring (fourth week of March). In these trials, the percentage of patients who were depression-free at the end of treatment was significantly higher for those on Wellbutrin XL than for those on placebo; for all 3 studies combined, the overall rate of patients depression-free at the end of treatment was 84 percent for those on Wellbutrin XL compared to 72 percent for those on placebo."
The drug's label includes a "black box" warning on the increased risk of suicidal thoughts and behavior in pediatric patients treated with antidepressants.
As sunlight patterns change in autumn and winter, there is a shift in the "biological internal clocks" or circadian rhythms, according to the National Mental Health Association. This can cause your biological clocks to be out of step with normal activities. January and February are the most difficult months for sufferers, and younger persons and women are at higher risk, the association says.
A Better Brew to Fight Prostate Cancer?
That beer you're holding may contain small amounts of a compound thought to prevent prostate cancer and enlargement, according to an Oregon State University study, but you'd have to drink almost a case to activate its benefits.
Researchers said that xanthohumol, which is found in the hops used to brew beer, belongs to a group of plant compounds called flavonoids that can trigger the death of cancer cells along the surface of the prostate gland, the Associated Press reported Monday.
Fred Stevens, an assistant professor of medicinal chemistry at OSU's College of Pharmacy, said it may be possible for drug companies to develop pills containing concentrated doses of the flavonoid and to increase the xanthohumol content of hops. The Oregon study findings were published in a recent issue of Cancer Letters.
German scientists have already developed a beer that contains 10 times the amount of xanthohumol as traditional brews. The drink is being marketed as a healthy beer, the AP said, but research is still under way to determine if it has any effect on cancer.
Still, there should no rush to belly up to the bar, according to the head of the National Prostate Cancer Coalition. "It's every mans dream to hear that beer and pizza can prevent cancer," said Dr. Richard N. Atkins in a prepared statement. "However, the 17 beers and four large pizzas needed to get enough xanthohumol and lycopene to help prevent prostate cancer is unfortunately not advised. Our hope is that men know the facts and get tested for prostate cancer. Food, no matter how helpful it may be, is not a full preventive for prostate cancer."
Diabetes Vision Drug Trials Show Promise
Eli Lilly and Co. says two late-phase trials of its experimental drug Arxxant reduced the risk of vision loss by 42 percent among patients with serious eye problems caused by diabetes. The drug, which is awaiting federal approval, could bring Lilly an estimated $1 billion a year, The Indianapolis Star reported Monday.
Since no drug currently treats the disorder, called diabetic retinopathy, the typical current treatment uses laser surgery in advanced stages of the illness.
Dr. Louis Vignati, medical director for Lilly's Arxxant product team, told the newspaper that stemming vision loss could improve the quality of life for many diabetics, allowing them to keep driving cars or taking part in other everyday activities.
The U.S. Food and Drug Administration has agreed to speed up its usual one-year review time for Arxxant, since there are no approved treatments for diabetic eye disease.
The drug maker revealed the findings over the weekend at the annual scientific meeting of the American Diabetes Association in Washington, D.C.
No comments:
Post a Comment